<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38735" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Benzoyl Peroxide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Matin</surname>
            <given-names>Taraneh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goodman</surname>
            <given-names>Marcus B.</given-names>
          </name>
          <aff>Philadelphia College of Osteopathic Med.</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Taraneh Matin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marcus Goodman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38735.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity explores benzoyl peroxide, an over-the-counter topical medication that is FDA-approved for addressing acne vulgaris. The educational content delves into its bactericidal properties, specifically targeting <italic toggle="yes">Cutibacterium acnes</italic> within the skin and hair follicles. This activity equips healthcare professionals with essential knowledge for effective utilization in clinical settings by focusing on indications, mechanisms of action, and safe administration practices. Critical components of this program include a thorough examination of adverse drug reactions, contraindications, drug-drug interactions, clinical toxicology, and the necessity of monitoring various physiological aspects during benzoyl peroxide use. The curriculum underscores the significance of understanding intricate pharmacology to enable tailored treatment plans aligned with individual patient needs. Prioritizing patient safety becomes paramount, particularly considering the distinctive characteristics of the targeted patient population.</p>
        <p>Through an evidence-based approach, this educational initiative empowers healthcare professionals to make informed decisions, keeping them updated on the latest guidelines and recommendations and facilitating the optimal integration of benzoyl peroxide into treatment regimens, ultimately enhancing outcomes for patients grappling with acne vulgaris.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for benzoyl peroxide use.</p></list-item><list-item><p>Evaluate&#x000a0;the mechanism of action of benzoyl peroxide.</p></list-item><list-item><p>Identify&#x000a0;the most common adverse effects associated with benzoyl peroxide use.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;benzoyl peroxide treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38735&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38735">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38735.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Benzoyl peroxide is an over-the-counter (OTC) topical medication and an FDA-approved prescription medication for acne vulgaris. Benzoyl peroxide is&#x000a0;bactericidal with activity against <italic toggle="yes">Cutibacterium acnes&#x000a0;</italic>(C<italic toggle="yes">. acnes</italic>) on the skin and within the hair follicles. Benzoyl peroxide has mild sebostatic and keratolytic effects and is most effective when combined with other acne vulgaris therapies.<xref ref-type="bibr" rid="article-38735.r1">[1]</xref><xref ref-type="bibr" rid="article-38735.r2">[2]</xref>&#x000a0;In contrast to other topical antibiotics, drug resistance has not appeared to develop with benzoyl peroxide use.<xref ref-type="bibr" rid="article-38735.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Acne vulgaris </bold>
</p>
        <p>As per the latest guidelines from the American Academy of Dermatology (AAD) in 2024, benzoyl peroxide is recommended for treating patients with acne. Additionally, the AAD suggests using fixed-dose combinations, such as topical retinoids with benzoyl peroxide, and endorses benzoyl peroxide&#x000a0;with topical retinoids&#x000a0;and&#x000a0;a topical antibiotic. The AAD also recommends incorporating systemic antibiotics with benzoyl peroxide and other topical therapies for acne management.<xref ref-type="bibr" rid="article-38735.r3">[3]</xref></p>
        <p>
<bold>Rosacea </bold>
</p>
        <p>The novel microencapsulated benzoyl peroxide 5% cream is a topical treatment option for moderate to severe papulopustular rosacea, effectively reducing papules, pustules, and telangiectasia.<xref ref-type="bibr" rid="article-38735.r4">[4]</xref></p>
        <p>
<bold>Off-Label&#x000a0;Uses&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Folliculitis, including gram-negative folliculitis, non-infectious folliculitis, and drug-induced folliculitis (acneiform eruptions)</p>
          </list-item>
          <list-item>
            <p>Pseudo-folliculitis barbae</p>
          </list-item>
          <list-item>
            <p>Progressive macular hypomelanosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pressure ulcers</p>
          </list-item>
          <list-item>
            <p>Perforating diseases</p>
          </list-item>
          <list-item>
            <p>Pitted keratolysis&#x000a0;<xref ref-type="bibr" rid="article-38735.r5">[5]</xref><xref ref-type="bibr" rid="article-38735.r6">[6]</xref><xref ref-type="bibr" rid="article-38735.r7">[7]</xref><xref ref-type="bibr" rid="article-38735.r8">[8]</xref><xref ref-type="bibr" rid="article-38735.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38735.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Topical benzoyl peroxide demonstrates bactericidal effects against <italic toggle="yes">Cutibacterium&#x000a0;acnes,</italic>&#x000a0;a key component of acne vulgaris.<xref ref-type="bibr" rid="article-38735.r1">[1]</xref><xref ref-type="bibr" rid="article-38735.r2">[2]</xref>&#x000a0;Following absorption through the skin, benzoyl peroxide undergoes conversion into benzoic acid.&#x000a0;Around 5% of the benzoic acid is absorbed systemically and then excreted by the renal system. The remaining benzoic acid is metabolized by cysteine in the skin, releasing active free-radical oxygen species and oxidizing bacterial proteins.<xref ref-type="bibr" rid="article-38735.r10">[10]</xref>&#x000a0;Improvement of acne vulgaris occurs by reducing lipids, free fatty acids, and&#x000a0;<italic toggle="yes">P. acnes</italic>.</p>
        <p>After applying 10% benzoyl peroxide daily for&#x000a0;2 weeks, the amount of&#x000a0;<italic toggle="yes">P. acnes&#x000a0;</italic>in hair follicles decreased by 98%, and the amount of free fatty acids decreased by 50%, comparable to results obtained after&#x000a0;4 weeks of antibiotic therapy.<xref ref-type="bibr" rid="article-38735.r11">[11]</xref>&#x000a0;Topical benzoyl peroxide also has mild sebostatic effects, contributing to its keratolytic activity and efficacy in treating comedonal acne.<xref ref-type="bibr" rid="article-38735.r1">[1]</xref>&#x000a0;Benzoyl peroxide effectively treats cutaneous ulcers through stimulation of healthy production of granulation tissue and rapid ingrowth of epithelium.<xref ref-type="bibr" rid="article-38735.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> In vitro studies using excised human skin and in vivo studies on rhesus monkeys demonstrate that benzoyl peroxide penetrates the skin layers and is converted to benzoic acid. Using formulations containing lower concentrations of benzoyl peroxide (2.5%) can minimize skin irritation, improving tolerability and treatment outcomes.<xref ref-type="bibr" rid="article-38735.r13">[13]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>The radiolabelled dose thoroughly penetrates the skin and recovers as benzoic acid. The dose in the skin is approximately half benzoic acid and half benzoyl peroxide.</p>
        <p><bold>Metabolism:</bold> The peroxide bond of benzoyl peroxide is cleaved to form 2 benzoyloxy radicals. Benzoic acid is a significant metabolite of benzoyl peroxide.</p>
        <p><bold>Elimination:</bold> Benzoic acid, the metabolite of benzoyl peroxide, is eliminated in the urine. Data regarding fecal elimination is not readily available.</p>
      </sec>
      <sec id="article-38735.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Benzoyl peroxide is commercially available in 2.5%, 5%, and 10% concentrations, both over-the-counter and prescription formulations. These products include lotions, creams, gels, foams, solutions, cleansing bars, lotions, cloths, pads, masks, and shaving creams. Benzoyl peroxide is also available in formulations such as benzoyl peroxide and clindamycin, benzoyl peroxide and erythromycin, benzoyl peroxide and adapalene, benzoyl peroxide and tretinoin, benzoyl peroxide and hydrocortisone, and benzoyl peroxide, clindamycin, and adapalene. Every vehicle application comes with instructions outlining the recommended frequency of use.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Cleansing bars and washes are used&#x000a0;1 to&#x000a0;3 times a day, whereas mask application is a thin layer left on for 15 to 25 minutes once a week.<xref ref-type="bibr" rid="article-38735.r14">[14]</xref>&#x000a0;Studies have shown that to treat acne vulgaris, the combination formulations containing benzoyl peroxide, adapalene, and topical antibiotics are more effective than either medication used alone.<xref ref-type="bibr" rid="article-38735.r15">[15]</xref><xref ref-type="bibr" rid="article-38735.r16">[16]</xref>&#x000a0;Combination preparations with erythromycin or clindamycin are applied twice daily, whereas combination preparations with adapalene are applied once daily.<xref ref-type="bibr" rid="article-38735.r14">[14]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dosage adjustments for hepatic impairment are specified in the product labeling for benzoyl peroxide.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments are provided for renal impairment in benzoyl peroxide's product labeling.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The FDA classifies benzoyl peroxide as pregnancy risk category C. The effects of benzoyl peroxide on reproductive health and fetal health are unknown. However, because of its minimal systemic absorption, topical application of benzoyl peroxide is generally considered safe during pregnancy. Applying 5% benzoyl peroxide twice daily is considered a safe acne treatment throughout all stages of pregnancy. Despite limited research, its perceived low risk is attributed to minimal systemic absorption and quick renal excretion.<xref ref-type="bibr" rid="article-38735.r17">[17]</xref><xref ref-type="bibr" rid="article-38735.r18">[18]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>There is insufficient data on using benzoyl peroxide while breastfeeding. Because of its low rate of systemic absorption, minimal risk to the infant is likely, and the topical use of benzoyl peroxide is generally considered safe while breastfeeding, as long as its application is not where the infant would have direct contact during breastfeeding or close skin-on-skin contact.<xref ref-type="bibr" rid="article-38735.r17">[17]</xref></p>
        <p><bold>Pediatric patients:</bold> Little data supports&#x000a0;benzoyl peroxide's clinical safety and efficacy when used in children. Because of its minimal systemic absorption, topical benzoyl peroxide is generally considered safe in the pediatric population.<xref ref-type="bibr" rid="article-38735.r19">[19]</xref>&#x000a0;</p>
        <p><bold>Older patients:&#x000a0;</bold>No dosage adjustments for older patients are provided in the product labeling.</p>
      </sec>
      <sec id="article-38735.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect of benzoyl peroxide is its bleaching quality, potentially causing the discoloration of colored fabrics and hair bleaching. At higher concentrations, topical benzoyl peroxide causes mild dryness, erythema, and scaling.<xref ref-type="bibr" rid="article-38735.r20">[20]</xref> There are also case reports of contact dermatitis in a small percentage of patients, which should arouse suspicion in patients who develop marked erythema and irritation at the treatment site. In such instances, the prudent course of action is stopping benzoyl peroxide.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should avoid concomitant use of topical sulfone products (eg, dapsone) with topical benzoyl peroxide&#x000a0;as it reportedly causes skin and facial hair yellowing.<xref ref-type="bibr" rid="article-38735.r21">[21]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients should avoid concomitant use of topical hydroquinone with topical benzoyl peroxide as it may result in increased skin irritation and transient staining of the epidermis.<xref ref-type="bibr" rid="article-38735.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant use of oral isotretinoin with topical benzoyl peroxide has&#x000a0;been reported to result in increased skin irritation and dryness.<xref ref-type="bibr" rid="article-38735.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients should avoid concurrent application of topical benzoyl peroxide with topical&#x000a0;tretinoin&#x000a0;as it decreases tretinoin's efficacy. Unlike tretinoin, adapalene is resistant to oxidation by benzoyl peroxide and is an acceptable combination product.<xref ref-type="bibr" rid="article-38735.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant use of topical anesthetics with topical benzoyl peroxide reportedly decreases the efficacy of anesthetics. For optimal results, the recommendation is to thoroughly wash the treatment area before applying topical anesthetics.<xref ref-type="bibr" rid="article-38735.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38735.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients who present with a known history of hypersensitivity to benzoyl peroxide should not use benzoyl peroxide products. Patients with hypersensitivity to cinnamon and other benzoic acid derivatives should be cautious when using benzoyl peroxide, as cross-reactivity may occur.<xref ref-type="bibr" rid="article-38735.r25">[25]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Benzoyl peroxide is not indicated for use around the eyes, nose, mouth, mucous membranes, and open skin, as it may cause severe irritation. For mucous membrane or ocular contact, thoroughly rinse affected areas with water for a minimum of 15 minutes. Patients should minimize UV exposure and apply sunscreen to reduce the risk of developing phototoxicity and skin irritation.<xref ref-type="bibr" rid="article-38735.r20">[20]</xref>&#x000a0;</p>
        <p>Some formulations of benzoyl peroxide may include high concentrations of propylene glycol or dimethyl sulfoxide, both of which have been associated with an increased risk of adverse events.<xref ref-type="bibr" rid="article-38735.r26">[26]</xref>&#x000a0;Propylene glycol, when used in high doses or for prolonged periods, can lead to toxicity. Clinical features of propylene glycol toxicity in children may include seizures, central nervous system (CNS) toxicity, cardiac arrhythmia, hyperosmolarity, agitation, hemolysis, and lactic acidosis.<xref ref-type="bibr" rid="article-38735.r26">[26]</xref><xref ref-type="bibr" rid="article-38735.r27">[27]</xref></p>
      </sec>
      <sec id="article-38735.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>No monitoring parameters were identified for benzoyl peroxide, and no routine tests are recommended. The development of contact dermatitis to benzoyl peroxide should be monitored, with discontinuation of the medication in patients who develop marked erythema and irritation with its use. Before using benzoyl peroxide, a test area should have a test treatment to monitor for tolerability and sensitivity.<xref ref-type="bibr" rid="article-38735.r20">[20]</xref><xref ref-type="bibr" rid="article-38735.r25">[25]</xref></p>
      </sec>
      <sec id="article-38735.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Topical benzoyl peroxide should not be taken by mouth; indications are strictly limited to topical use.&#x000a0;In case of ingestion, patients should call 911, contact the poison control center (1-800-222-1222), or report to the nearest emergency department. There are no known antidotes for this medication.</p>
      </sec>
      <sec id="article-38735.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The most common medications prescribed for acne vulgaris by clinicians include&#x000a0;benzoyl peroxide, retinoids, and topical/oral antibiotics. Rosacea and refractory cases of acne vulgaris may require consultation with a dermatologist. Pharmacists should educate patients about adverse drug reactions. Nurses should explain the importance of compliance. Despite their efficacy in treating mild-to-moderate acne vulgaris, studies have shown that combining antibiotics or retinoids with benzoyl peroxide is more productive than using either medication alone. The combination is believed to be synergistic and has also been shown to prevent the development of antibiotic resistance.<xref ref-type="bibr" rid="article-38735.r2">[2]</xref><xref ref-type="bibr" rid="article-38735.r15">[15]</xref>&#x000a0;However, in a survey of patients with an indication for benzoyl peroxide as an additional acne treatment, only 30% of the patients obtained the benzoyl peroxide product.<xref ref-type="bibr" rid="article-38735.r28">[28]</xref> Therefore, to improve patient compliance and treatment efficacy, healthcare providers should seek to prescribe combination products that would result in simpler skincare regimens and greater patient adherence.</p>
        <p>The initial disadvantage of combination products is their increased cost and&#x000a0;need to be refrigerated to prevent degradation.<xref ref-type="bibr" rid="article-38735.r14">[14]</xref> Although refrigeration is encouraged, cost reduction is possible through the utilization of specialty compounding pharmacies.&#x000a0;An interprofessional team approach between clinicians (MDs, DOs, NPs, PAs), pharmacists, dermatologists, and nurses is necessary to&#x000a0;optimize patient outcomes with&#x000a0;benzoyl peroxide.</p>
      </sec>
      <sec id="article-38735.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38735&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38735">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38735/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38735">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38735.s11">
        <title>References</title>
        <ref id="article-38735.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kircik</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>The role of benzoyl peroxide in the new treatment paradigm for acne.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2013</year>
            <month>Jun</month>
            <day>01</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>s73</fpage>
            <page-range>s73-6</page-range>
            <pub-id pub-id-type="pmid">23839205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Acne Vulgaris.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Oct</month>
            <day>04</day>
            <volume>379</volume>
            <issue>14</issue>
            <fpage>1343</fpage>
            <page-range>1343-1352</page-range>
            <pub-id pub-id-type="pmid">30281982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reynolds</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cook-Bolden</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Druby</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Keri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JKL</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of acne vulgaris.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2024</year>
            <month>May</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>1006.e1</fpage>
            <page-range>1006.e1-1006.e30</page-range>
            <pub-id pub-id-type="pmid">38300170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Lain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prunty</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rhoades</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>36</fpage>
            <page-range>36-40</page-range>
            <pub-id pub-id-type="pmid">35642224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Topical treatment for the inflamed lesion in acne, rosacea, and pseudofolliculitis barbae.</article-title>
            <source>Cutis</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>6 Suppl</issue>
            <fpage>4</fpage>
            <page-range>4-5</page-range>
            <pub-id pub-id-type="pmid">15228127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>XG</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>XZ</given-names>
              </name>
            </person-group>
            <article-title>A case of progressive macular hypomelanosis successfully treated with benzoyl peroxide plus narrow-band UVB.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>367</fpage>
            <page-range>367-8</page-range>
            <pub-id pub-id-type="pmid">20524876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez Vozmediano</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Alonso Blasi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Almenara Barrios</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alonso Trujillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lafuente</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Benzoyl peroxide in the treatment of decubitus ulcers].</article-title>
            <source>Med Cutan Ibero Lat Am</source>
            <year>1988</year>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-9</page-range>
            <pub-id pub-id-type="pmid">3070200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luk&#x000e1;cs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schliemann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acquired reactive perforating dermatosis - a systematic review.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>825</fpage>
            <page-range>825-842</page-range>
            <pub-id pub-id-type="pmid">29927512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlahovic</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The use of a clindamycin 1%-benzoyl peroxide 5% topical gel in the treatment of pitted keratolysis: a novel therapy.</article-title>
            <source>Adv Skin Wound Care</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>564</fpage>
            <page-range>564-6</page-range>
            <pub-id pub-id-type="pmid">19935134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nacht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Anjo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Benzoyl peroxide: percutaneous penetration and metabolic disposition.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1981</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">7204686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nacht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gans</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>McGinley</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kligman</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Comparative activity of benzoyl peroxide and hexachlorophene. In vivo studies against propionibacterium acnes in humans.</article-title>
            <source>Arch Dermatol</source>
            <year>1983</year>
            <month>Jul</month>
            <volume>119</volume>
            <issue>7</issue>
            <fpage>577</fpage>
            <page-range>577-9</page-range>
            <pub-id pub-id-type="pmid">6222704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Meara</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cullum</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Majid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sheldon</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of antimicrobial agents used for chronic wounds.</article-title>
            <source>Br J Surg</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-21</page-range>
            <pub-id pub-id-type="pmid">11136304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harper</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Benzoyl peroxide development, pharmacology, formulation and clinical uses in topical fixed-combinations.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2010</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>482</fpage>
            <page-range>482-7</page-range>
            <pub-id pub-id-type="pmid">20480791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zeichner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kircik</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Topical Vehicle Formulations in the Treatment of Acne.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>s6</fpage>
            <page-range>s6-s10</page-range>
            <pub-id pub-id-type="pmid">29879262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Wortzman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%.</article-title>
            <source>Cutis</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>82</volume>
            <issue>6</issue>
            <fpage>417</fpage>
            <page-range>417-21</page-range>
            <pub-id pub-id-type="pmid">19181031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Thiboutot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shalita</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea.</article-title>
            <source>Cutis</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>6 Suppl</issue>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">15228129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pugashetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acne vulgaris in pregnant patients.</article-title>
            <source>Dermatol Ther</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>302</fpage>
            <page-range>302-11</page-range>
            <pub-id pub-id-type="pmid">23914887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manjaly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mostaghimi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Acne Vulgaris During Pregnancy and Lactation: A Narrative Review.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-130</page-range>
            <pub-id pub-id-type="pmid">36447117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coughlin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Swink</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Horwinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sfyroera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bugayev</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grice</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>The preadolescent acne microbiome: A prospective, randomized, pilot study investigating characterization and effects of acne therapy.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-664</page-range>
            <pub-id pub-id-type="pmid">29024079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Romita</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angelini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonamonte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Contact dermatitis to topical acne drugs: a review of the literature.</article-title>
            <source>Dermatol Ther</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>323</fpage>
            <page-range>323-9</page-range>
            <pub-id pub-id-type="pmid">26302055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubina</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.</article-title>
            <source>Arch Dermatol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>145</volume>
            <issue>9</issue>
            <fpage>1027</fpage>
            <page-range>1027-9</page-range>
            <pub-id pub-id-type="pmid">19770443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saade</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Maymone</surname>
                <given-names>MBC</given-names>
              </name>
              <name>
                <surname>Secemsky</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Vashi</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Patterns of Over-the-counter Lightening Agent Use among Patients with Hyperpigmentation Disorders: A United States-based Cohort Study.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>26</fpage>
            <page-range>26-30</page-range>
            <pub-id pub-id-type="pmid">30057662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chernyshov</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Tomas-Aragones</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manolache</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marron</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Bettoli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jemec</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>1410</fpage>
            <page-range>1410-1419</page-range>
            <pub-id pub-id-type="pmid">29729107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burkhart</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Burkhart</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide.</article-title>
            <source>Dermatol Surg</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11 Pt 1</issue>
            <fpage>1479</fpage>
            <page-range>1479-80</page-range>
            <pub-id pub-id-type="pmid">16416626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shwereb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Delayed type hypersensitivity to benzoyl peroxide.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2004</year>
            <season>Mar-Apr</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-9</page-range>
            <pub-id pub-id-type="pmid">15098979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>Benzoyl Peroxide Microsphere Formulations: What is the Science Supporting Microsphere Vehicle Technology and Clinical Use?</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>46</fpage>
            <page-range>46-54</page-range>
            <pub-id pub-id-type="pmid">20729960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pageler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Propylene glycol toxicity in children.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-82</page-range>
            <pub-id pub-id-type="pmid">25762872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38735.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huyler</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Adherence to over-the-counter benzoyl peroxide in patients with acne.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>763</fpage>
            <page-range>763-764</page-range>
            <pub-id pub-id-type="pmid">28917458</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
